Anjali S. Advani

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

Hagop M. Kantarjian, Daniel J. DeAngelo, Matthias Stelljes et al. · New England Journal of Medicine · 2016 · 1.3K citations · Full text

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403

Wendy Stock, Selina M. Luger, Anjali S. Advani et al. · Blood · 2019 · 454 citations · Full text

Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

Hagop M. Kantarjian, Deborah A. Thomas, Jeffrey L. Jorgensen et al. · The Lancet Oncology · 2012 · 410 citations

Inotuzumab Ozogamicin, Lymphoid Neoplasia, Hematological Malignancy +12

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

Mark J. Levis, Farhad Ravandi, Eunice S. Wang et al. · Blood · 2011 · 395 citations · Full text

Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study

Anjali S. Advani, Bertrand Coiffier, Myron S. Czuczman et al. · Journal of Clinical Oncology · 2010 · 329 citations · Full text

Novel Immunoconjugate, Immunology, Pharmacotherapy +19